Compugen Ltd., a therapeutic product discovery company, engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates primarily in the United States, Europe, and Israel. It focuses on the therapeutic proteins and monoclonal antibodies to address unmet needs in the fields of immunology and oncology. The company's therapeutic proteins pipeline includes CGEN-15001, a novel protein for the treatment of autoimmune disorders; CGEN-15021, a novel fusion protein for the treatment of multiple sclerosis, rheumatoid arthritis, and other autoimmune diseases; CGEN-15091, a novel fusion protein for the treatment of multiple sclerosis and autoimmune diseases; CGEN-15031, a fusion protein candidate to treat multiple sclerosis; and CGEN-15051, a fusion protein candidate for the treatment of rheumatoid arthritis. Its monoclonal antibody therapy product candidates include CGEN-15001T, a membrane protein target for the treatment of cancer; CGEN-15022 membrane protein for the treatment of multiple cancers; CGEN-671, a novel drug target for the treatment of multiple epithelial tumors; and CGEN-928 drug target for the treatment of multiple myeloma. Compugen Ltd. was founded in 1993 and is headquartered in Tel Aviv, Israel.
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | -2082.72% | -5631.40% |
| Operating margin | -2446.91% | -5595.87% |
| EBITD margin | - | -5472.31% |
| Return on average assets | -43.28% | -47.00% |
| Return on average equity | -68.65% | -73.16% |
| Employees | 52 | - |
Address
72 Pinchas Rosen St.
TEL AVIV-YAFO, 69512
Israel
TEL AVIV-YAFO, 69512
Israel
Website links http://cgen.com/
No comments:
Post a Comment